Neuberger Berman Group LLC Coherus Bio Sciences, Inc. Transaction History
Neuberger Berman Group LLC
- $114 Billion
- Q1 2025
A detailed history of Neuberger Berman Group LLC transactions in Coherus Bio Sciences, Inc. stock. As of the latest transaction made, Neuberger Berman Group LLC holds 18,030 shares of CHRS stock, worth $13,883. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,030Holding current value
$13,883% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CHRS
# of Institutions
123Shares Held
64.5MCall Options Held
96.6KPut Options Held
65.3K-
Black Rock Inc. New York, NY11.8MShares$9.05 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.2MShares$8.59 Million0.0% of portfolio
-
Rubric Capital Management LP New York, NY5.26MShares$4.05 Million0.12% of portfolio
-
Tang Capital Management LLC San Diego, CA5.1MShares$3.92 Million0.27% of portfolio
-
Kohlberg Kravis Roberts & Co. L.P. New York, NY3.04MShares$2.34 Million0.11% of portfolio
About Coherus BioSciences, Inc.
- Ticker CHRS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,724,600
- Market Cap $59.8M
- Description
- Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...